



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

CVMP activities regarding antimicrobials – Ongoing and recent activities

European Medicines Agency/IFAH-Europe Info Day 2016





Overview

- Guidelines
- Reflection papers
- Requests from European Commission for Opinions
- Other CVMP activities on antimicrobials
- Positive opinions for VMP applications and Referrals on antimicrobials



Guidelines (GL)

Guideline on demonstration of Efficacy for VMPs containing antimicrobial substances (EMA/CVMP/627/01-Final)

After 2 public consultations and a focus group meeting, adopted by CVMP in Jan 2016; comes into effect 1 Aug 2016

Amendments address -

- MIC determination (ECOFFs, Clinical BPs)
- Clarification on the role of PK/PD in dose justification
- Guidance on requirements for “reserved” substances (CIAs)
- Study design for metaphylaxis and prevention claims; selection of control groups



Draft Guideline on the assessment of the risk to public health from AMR due to the use of antimicrobial VMPs in food-producing animals (EMA/CVMP/AWP/706442/2013)

Public consultation ended 31 Aug 2015; comments from 6 interested parties. Key concerns –

- Transmission of AMR via **direct contact route**
- **Categorisation of risk factors** (H/M/L) and integration for overall risk characterisation
- **Availability of data for Exposure and Consequence assessments**

Also,

- *Exemption of generics, Environmental transmission of AMR*

Further consideration is being given to the 3 key issues indicated above



GL on the SPC for Antimicrobial VMPs

(EMA/CVMP/SAGAM/383441/2005)

To start revision in 2016 to include:

- (1) **Q&A document on pack sizes** for antimicrobials
(EMA/CVMP/EWP/686861/2014) Adopted by CVMP Feb 2016

Request from HMAv. Addresses concerns relating to
(i) availability of sufficiently small pack-sizes to enable treatment without wastage, (ii) pack sizes that are too large to be justified by the indications, dose regimen etc

→ pack size(s) should be justified.

- (2) To address **revisions to the Antimicrobials Efficacy GL**,
e.g. terminology relating to Metaphylaxis, responsible use warnings



Reflection papers (RP)

RP on Off-label use of antimicrobials in domestic animals

- Discusses the circumstances behind off-label use (*e.g. unmet medical needs, individual patient characteristics, practical considerations*) and how this can be in line with both responsible use and misuse
- Highlights the lack of information available on the extent of OLU in the EU
- CVMP is considering its recommendations
- To be published for public consultation shortly



Aminoglycosides and Extended-spectrum Penicillins (AWP)

AMEG recommended further risk-profiling to determine if they should be placed in category 2 (higher risk to public health)

RP on Aminoglycosides

- Advice sought from human Infectious Diseases WP regarding AGs considered as “last resort” to treat human diseases – One Health approach
- To be released for public consultation soon

RP on ES-Penicillins

- Public consultation for the Concept Paper ended 31 Oct 2015
- Concerns relate to these substances being placed at same level of restriction as FQs and 3/4G Cephalosporins. Drafting started.



Requests for scientific opinions from the European Commission

Update to the AMEG opinion on Colistin following identification of **MCR-1** mechanism of resistance (*Liu et al, 2015*)

AMEG advice to the Commission (2013) advised that if a transferable mechanism of colistin resistance was identified, a new risk assessment would be required.

- Mandate received from EC in Dec 2015 to consider if previous recommendations remain valid
- Representatives from CVMP, CHMP, ECDC, EFSA, JIACRA, EURL AR
- EMA to place a public call for data (closed 15 Mar) followed by a **short consultation period by the end of May / beginning of June 2016**
- Deadline for response to EC: **30 Jun 2016**



“RONAFA”: Joint EFSA /EMA opinion on measures to reduce the need to use antimicrobial agents in animal husbandry in the EU and the resulting impacts on food safety

- (1) *Measures that have been taken to **reduce the need for, and use of**, antimicrobials in animals and the **impact** of those measures on AMR* - Starting point - EC's Prudent Use Guidelines: prescribing, monitoring of use, training & education (CVMP, AWP)
- (2) ***Possible alternatives** to use of antimicrobials and **impacts** - husbandry, disease eradication, vaccination programmes, alternative therapies (Biohaz, AHAW panel)*
- (3) ***Recommendations** – including attention to minimising PH risk where there is continued need for AMs in animals.*



RONAFA contd.

- No public consultation foreseen
- Will use responses to FVO questionnaire on the application of the PUGLs in member states as a resource
- Also, questionnaires to veterinary professionals and food producers and retailers
- Deadline for RONAFA response to EC: **Dec 2016**



Other CVMP activities on antimicrobials

CVMP Strategy on Antimicrobials 2016 to 2020

The proposed 6 key aims broadly address:

- CVMP's role in **assessing applications for antimicrobial VMPs**;
- AMR **public health risk** from VMPs;
- **Maintaining the effectiveness** of antimicrobials in animals;
- **Encouraging the development** of new antimicrobial VMPs and alternatives;
- **Responsible use**;
- **EU and International collaboration**.

Public consultation ended 18 Feb 2016



Veterinary Committee on Antimicrobial Susceptibility testing: VetCAST

- Subcommittee of EUCAST
 - Goal is to become the EU scientific-based operational body for definition/approval of **veterinary-specific breakpoints** (BPs) and **harmonisation of AST**
 - VetCAST would like to provide CVMP with advice on breakpoints in the same way as EUCAST advises CHMP – ***under discussion***
 - MAH involvement voluntary; MAH $\leftrightarrow$ VetCAST agreement to share data
 - Value: Clinical BPs help establish effective dose regimens; vets when making prescribing decisions; extend availability of older AM products
- CVMP recognises that industry has concerns and EMA/CVMP will develop a strategy involving the parties concerned to explore ways to take forward.*



CVMP referrals and positive opinions 2015/16

Article 35

- **Lincomycin and spectinomycin combinations** administered orally to pigs and poultry / indications, dosing regimens, WPs/ on-going
- **Colistin in combination with other antimicrobials** for oral administration / follow up to AMEG advice on colistin (2013) / on-going
- **Zinc oxide** / ERA and AMR / initiated Feb 2016

Article 34

- **Denagard 45 % oral granules** (tiamulin) / on-going

Positive opinions

- **Zactran injection** (gamithromycin) – extension to treat swine respiratory disease
- **Draxxin injection** (tulathromycin) –add *Bordetella bronchiseptica* to SRD



Thank you for listening!

